![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, February 20, 2020 7:00:13 PM
I suspect the next thing to happen may be the initiation of the Phase 2 Trial in psoriasis, and they may, or may not tell us about it. I do believe after a decision is made to go into the blinded portion of the trial they'll tell us so. Remember the first part of the trial is intended to determine the best does to use in the blinded trial, and in that they see the results, I'm hoping we will as well.
There are people who create doubt because things like Phase 1 trial results are not presented for peer review, check other companies, I believe you'll find that's the case with nearly all of them. The fact that safety is established in Phase 1 is clear because Phase 2 is being initiated. In our case, the Phase 1 was done in healthy people, so no indication of efficacy was possible, the cream is safe, no peer review required.
I suspect that if the work the company has done were being done here in the U.S. the cost would probably be ten times or more than what's been spent, or is needed to complete Phase 2's. It's not impossible to gain approval in Phase 2, at least for a limited number of countries. I suspect the U.S. would insist on a Phase 3 with at least some trial sites being here in the U.S., the cost will be far higher, and they'll probably need a partner before they can do it unless they do have approvals in at least a few countries generating the funds necessary to do it.
Much the same will be true for the sublingual tablet, etc. IMHO they don't proceed until patent approval is established.
Gary
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM